The biggest microbiome market may not be a microbiome market.
A much larger opportunity may come from businesses embedding microbiome capabilities inside something customers already value.
The category is not the market.
We tend to measure the microbiome market by counting the companies that carry the word. More tests, supplements, therapeutics and platforms appear, and we assume that a larger category will follow.
That may be the wrong unit of analysis. The larger commercial opportunity may sit in businesses that never ask a customer to buy “the microbiome” at all. A diagnostic service could use microbial information to improve a clinical decision. A food company could use it to design a better product. An agricultural business could use it to make an existing production system more resilient.
In each case, the buyer pays for an outcome they already understand. The microbiome is part of how the business delivers it.
Invisible capability can create visible value.
This changes the question for specialist companies. It is tempting to ask how to make more customers care about microbiome science. A more useful question may be: whose existing proposition becomes better when our capability is inside it?
That is a different route to market. The buyer may be a laboratory, a food producer, a care provider or a technology platform. The work is to understand the decision they make, the evidence they need and the economics of adding another capability. A partnership is valuable only when it changes what that organisation can offer its own customers.
Being embedded can make the specialist less visible. It can also make the capability more widely used. The choice is strategic, not a question of scientific pride.
Build the product, enable someone else’s, or do both.
There will still be successful microbiome companies with products of their own. But building a category around every scientific advance is expensive. It requires the specialist to create demand, educate buyers, establish trust and often construct a route to adoption almost from scratch.
Other companies may scale further by becoming an essential layer in markets that already exist. Some will do both, using their own product to prove the capability while enabling partners to take it into other settings.
The hard part is deciding where control really matters. What must the specialist own to protect quality and value? What can a partner deliver better because it already has the customer relationship, infrastructure or place in a workflow? Those choices shape the business model more than the category label does.
In 2035, there may be fewer microbiome companies. But far more microbiome-enabled businesses.